AstraZeneca Pharmaceuticals LP
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
AstraZeneca is divesting two cardiovascular drugs to Germany’s Cheplapharm Arzneimittel GmbH for $400 million, which will allow the UK pharma giant to reinvest in its main therapy areas.
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
Days after the U.S. FDA greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.
After nearly a month in limbo, AstraZeneca will resume Phase III testing of its COVID-19 vaccine candidate in the United States.
It was another busy week for clinical trial updates and news. Here’s a look.
Shares of AstraZeneca dropped slightly Wednesday afternoon following reports that a patient participating in the Brazilian arm of the company’s global Phase III study has died.
JOBS
IN THE PRESS